Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-12-21
2010-10-12
Shameem, Golam M. M. (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S256000, C514S303000, C514S326000, C514S341000, C514S364000, C514S365000, C514S378000, C514S397000, C514S398000, C544S333000, C544S405000, C546S119000, C546S210000, C546S274700, C548S126000, C548S200000, C548S248000, C548S255000, C548S311400, C548S311700, C548S315100, C548S315400, C548S332100
Reexamination Certificate
active
07812026
ABSTRACT:
The present invention relates to novel imidazole derivatives having a positive allosteric GABABreceptor (GBR) modulator effect, methods for the preparation of said compounds and to their use, optionally in combination with a GABABagonist, for the inhibition of transient lower esophageal sphincter relaxations, for the treatment of gastroesophageal reflux disease, as well as for the treatment of functional gastrointestinal disorders and irritable bowel syndrome (IBS). The compounds are represented by the general formula (I) wherein R1, R2, R3and R4are as defined in the description. For example, R1may be phenyl, R2may be dimethylamino pyrrolidin-1-yl, R3may be alkoxy and R4may be alkyl, ai arylalkyl, aryloxyalkyl, aryloxy or heterocyclylalkyl.
REFERENCES:
patent: 3876655 (1975-04-01), Heyes et al.
patent: 4659720 (1987-04-01), Chabala et al.
patent: 5162364 (1992-11-01), Debaert et al.
patent: 5214063 (1993-05-01), Debaert et al.
patent: 5278166 (1994-01-01), Debaert et al.
patent: 5304685 (1994-04-01), Merger et al.
patent: 6448282 (2002-09-01), Phillips et al.
patent: 2004/0077645 (2004-04-01), Himmelsbach et al.
patent: 2004/0259883 (2004-12-01), Sakashita et al.
patent: 2008/0262064 (2008-10-01), Bauer et al.
patent: 2008/0269216 (2008-10-01), Bauer et al.
patent: 2008/0312291 (2008-12-01), Bauer et al.
patent: 2008/0312305 (2008-12-01), Bauer et al.
patent: 2009/0005428 (2009-01-01), Bauer et al.
patent: 2009/0023704 (2009-01-01), Cheng et al.
patent: 2009/0062365 (2009-03-01), Bauer et al.
patent: 2009/0149474 (2009-06-01), Bauer et al.
patent: 449046 (1963-07-01), None
patent: 269238 (1988-06-01), None
patent: 181833 (1990-05-01), None
patent: 356128 (1992-07-01), None
patent: 399949 (1995-04-01), None
patent: 2722192 (1996-01-01), None
patent: WO-94/19351 (1994-09-01), None
patent: WO-97/31900 (1997-09-01), None
patent: WO-98/11885 (1998-03-01), None
patent: WO 00/53596 (2000-09-01), None
patent: WO-01/41743 (2001-06-01), None
patent: WO-01/42252 (2001-06-01), None
patent: WO-01/90141 (2001-11-01), None
patent: WO-02/00651 (2002-01-01), None
patent: WO-03/090731 (2003-11-01), None
patent: WO 2004/018468 (2004-03-01), None
patent: WO-2006/01750 (2006-01-01), None
Nielson et al. “Phosphorus Pentoxide in Organic Synthesis-I.” Tetrahedron vol. 38, No. 10, pp. 1435-1441, 1982.
Binet et al., “The Heptahelical Domain of GABAB2is Activated Directly by CGP7930, a Positive Allosteric Modulator of the GABABReceptor”, Journal of Biological Chemistry 2004, 279(28), 29085-91.
Bream et al., European Journal of Medicinal Chemistry (1981), 16, 175-179.
Brice et al., “Metabotropic glutamate and GABAB receptors contribute to the modulation of glucose-stimulated insulin secretion in pancreatic beta cells,” Diabetologia, 2002, 45, p. 242-52.
Carruthers et al., “Synthesis of a Series of Sulfinic Acid Analogs of GABA and Evaluation of Their GABABReceptor Affinities”, Bioorg. & Med. Chem. Lett. (1998), 8, 3059-3064.
Coward et al., “Chimeric G Proteins Allow a High-Throughput Signaling Assay of G1-Coupled Receptors”, Anal. Biochem. (1999) 270, 242-248.
Drossman et al. Rome II: A multinational consensus document on Functional Gastrointestinal Disorders, Gut, 1999, 45 (Suppl. 2), II 1-II 81, Sep. 1, 1999.
Froestl et al., “Phosphinic Acid Analogues of GABA. 1. New Potent and Selective GABAsAgonists”, J. Med. Chem. (1995), 38, 3297-3312.
Gewald et al., “4-Amino-imidazole durchThorpe-Cyclisierung”, Monatshefte für Chemie (1976), 107: 1413-1421.
Gompper et al., Tetrahedron Lett. (1966), 1885-1889.
Henze et al., Journal of Organic Chemistry (1953), 18, 653-656.
Holloway et al., Gastroenterol. Clin. N. Amer. 1990, 19, 517-535.
Holloway, Richard, “Systematic Pharmacomodulation of Transient Lower Esophageal Sphincter Relaxations”, Am. J. Med., 2001, 111(8A), 178s-185s.
D. L. Huges in Organic Reactions, vol. 42, p. 335-656 (1992).
Huppatz, Australian J. Chem. (1985), 38, 221-230.
Kerr et al., “Arylalkylamines are a Novel Class of Positive Allosteric Modulators at GABABReceptors in Rat Neocortex”, European Journal of Pharmacology 2002, 451(1), 69-77.
Kerr et al., “Metabotropic GABABReceptors: New Challenges in Drug Design”, Curr. Med. Chem.-Central Nervous System Agents (2001), 1, 27-42.
Krogsgaard-Larsen et al.: “GABAA and GABAB receptor agonists, partial agonists, antagonists and modulators: design and therapeutic prospects,” Eur. J. Pharm. Sci. 1997, (5), 355-84.
Lidums et al., “Control of Transient Lower Esophageal Sphincter Relaxations and Reflux by the GABABAgonist Baclofen in Normal Subjects”, Gastroenterology 2000, 118, 7-13.
Ludovici et al., “Evolution of Anti-HIV Drug Candidates, Part 1: From—Anilinophenylacetamide (-APA) to Imidoyl Thiourea (ITU)”, Bioorg. Med. Chem. Lett. 2001, 11, 2225-2228.
Mcatee et al., “Novel Substituted 4-phenyl-[1,3]dioxanes: Potent and Selective Orexin Receptor 2 (OX2R) Antagonists”, Bioorg. Med. Chem. Lett. 2004, 14, 4225-4229.
Mittal et al., “Transient Lower Esophageal Sphincter Relaxation.” Gastroenterology (1995) 109, pp. 601-610.
Nielsen et al., “Phosphorus Pentoxide-Amine Hydrochloride Mixtures as Reagents in a New Synthesis of Hypoxanthines”, Tetrahedron (1982), 38: 1435-1441.
Onali et al., “Positive Regulation of GABABReceptors Dually Coupled to Cyclic AMP by the Allosteric Agent CGP7930”, European Journal of Pharmacology 2003, 471(2), 77-84.
Pin et al., “Positive Allosteric Modulators for ÿ-Aminobutyric AcidBReceptors Open New Routes for the Development of Drugs Targeting Family 3 G-Protein-Coupled Receptors”, Molecular Pharmacology, 2001, 60(5), 881-4.
Rappoport et al., J. Org. Chem. (1982), 47, 1397-1408.
Ried et al., Chemische Berichte (1983), 116, 1547.
Ried et al., Liebigs Annalen der Chemie (1986), 4, 780.
Schmidt et al., Helvetica Chimica Acta (1959), 42, 349-359.
Shiori, J. Org. Chem. (1978), 43, 3631-3632.
Slätt et al., Journal of Heterocyclic Chemistry (2005), 42, 141-145.
Soudijn et al., “Allosteric Modulation of G Protein-Coupled Receptors”, Current Opinion in Drug Discovery and Development 2002, 5(5), 749-55.
Soudijn et al., “Expert Opinion” Ther. Patents (2001), 11, 1889-1904.
STN International, file CAPLUS, CAPLUS Accession No. 1982:616123, Document No. 97:216123, Nielsen, F.E. et al. “Phosphorous pentoxide in organic synthesis. 1. Phosphorous pentoxide-amine hydrochloride mixtures as reagents in a new synthesis of hypoxanthines”, Tetrahedron (1982), 38, (10), p. 1435-1441.
STN International, file CAPLUS, CAPLUS Accession No. 2002:10470, Document No. 136:85810, DuPont Pharmaceuticals Company “Preparation of arylamides and heterocyclylamides as factor Xa inhibitors for treatment of thromboembolic disorders”; WO 2002/000651 A2, 20020103.
Lwowski, Synthesis (1971), 5, 263.
Yu et al., Synthesis (2004), 7, 1021-1028.
Golankiewicz et al., Tetrahedron (1985), 41, 5989-5994.
Thompson et al., “Functional Bowel Disorders and Functional Abdominal Pain”. In: Drossman et al, eds. Rome II: Functional Gastrointestinal Disorders: Diagnosis, Pathophysiology and Treatment. 2 ed. McLean, VA: Degnon Associates, Inc.; 2000: 351-432.
Urwyler et al., “N,N′-Dicyclopenty1-2-methylsulfany1-5-nitro-pyrimidine-4, 6-diamine (GS39783) and Structurally Related Compounds: Novel Allosteric Enhancers of γ-Aminobutyric AcidBReceptor Function”, The Journal of Pharmacology and Experimental Therapeutics, 307 (2003), 322-330.
Urwyler et al., “Positive Allosteric Modulation of Native and Recombinant γ-Aminobutyric AcidBReceptors by 2, 6-Di-tert-butyl-4-(3-hydroxy-2,2-dimethyl-propyl)-phenol (CGP7930) and its Aldehyde Analog CGP13501”, Society for Neuroscience, 30th Annual Meeting, New Orleans, La., Nov. 4-9, 2000: Positive Allosteric Modulation of Native and Recombinant GABAB Receptor Activity, S.
Bauer Udo
Brailsford Wayne
Gustafsson Linda
Svensson Tor
AstraZeneca AB
Fierro Alicia L
Shameem Golam M. M.
White & Case LLP
LandOfFree
Imidazole derivatives having a positive allosteric GABA B... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Imidazole derivatives having a positive allosteric GABA B..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Imidazole derivatives having a positive allosteric GABA B... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4191735